Codon-Optimized BSEP AAV Therapy to Restore PFIC2 Liver Function
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no effective cure for progressive familial intrahepatic cholestasis type 2 (PFIC2), a genetic disease causing bile acid accumulation leading to liver failure and increased risk of hepatocellular carcinoma, with existing treatments like ursodeoxycholic acid therapy providing only symptom relief and liver transplants carrying significant risks.
Innovation Solution
A codon-optimized adeno-associated virus (AAV) vector is used to deliver a bile salt export pump (BSEP) gene to the liver, achieving stable and long-term expression in hepatocytes, thereby restoring bile salt secretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If liver transplant is performed to treat PFIC2, then liver function is restored, but surgical risks and procedure complexity increase
Solution Approach 1:
The patent uses an AAV vector as an intermediary carrier to deliver the codon-optimized BSEP gene to hepatocytes. This viral vector mediates gene transfer without requiring surgical intervention, thus restoring liver function while avoiding the complexity and risks of liver transplantation surgery.
Solution Approach 2:
The patent replaces the mechanical surgical intervention (liver transplant) with a molecular-level intervention (gene therapy). By substituting the mechanical surgical system with a biochemical gene delivery system, the treatment achieves liver function restoration without surgical complexity.
2Ease of manufacture
If standard BSEP gene therapy is used, then treatment approach is simple, but transgene expression is insufficient and unstable
Solution Approach 1:
The patent applies codon optimization to the BSEP gene sequence, changing the nucleotide parameters while maintaining the amino acid sequence. This parameter change at the DNA level enhances translation efficiency and protein expression stability, thereby improving transgene expression reliability while keeping the treatment approach relatively simple.
Solution Approach 2:
The patent introduces liver-specific promoter elements and regulatory sequences at specific locations in the gene construct to enhance expression in target hepatocytes. This local quality enhancement at specific genomic regions improves overall transgene expression stability without complicating the entire treatment methodology.
3Ease of operation
If ursodeoxycholic acid therapy is administered, then symptom relief is achieved, but disease cure is not attained
Solution Approach 1:
The patent uses the codon-optimized BSEP gene as a molecular intermediary to restore the defective bile salt export function. Unlike symptomatic drug therapy, this gene intermediary directly addresses the underlying genetic defect, enabling disease cure rather than merely managing symptoms.
Solution Approach 2:
The patent performs preliminary correction of the genetic defect by delivering the functional BSEP gene before irreversible liver damage occurs. This preliminary genetic intervention prevents disease progression and achieves cure, rather than merely managing symptoms after damage has occurred.
Data Source
AI summary
A gene therapy vector is used in the treatment of progressive familial intrahepatic cholestasis type 2. More specifically, an adeno-associated virus vector includes codon-optimized sequence encoding for the BSEP for the treatment of PFIC2.